先看重点
在英国高血压成人中随访长达21年,就诊间收缩压变异性独立于平均血压预测心血管事件(每5 mmHg的HR为1.22),基于氨氯地平的治疗在卒中方面优于基于阿替洛尔的治疗(HR 0.82)。变异性介导获益的说法来自试验后的观察性模型分析。
证据类型
研究论文
解读依据
公开摘要
阅读重点
方法与适用范围
研究在问什么
就诊间血压波动大预示心脏事件风险,但一段时间内血压控制相同而变异性不同,对长期结局有何影响并不清楚。作者延长了ASCOT-BPLA的随访,分析试验期间平均血压和变异性与日后事件的关系。
研究了谁,如何研究
对ASCOT-BPLA英国参与者的延长随访:高血压成人(4305人分配至氨氯地平±培哚普利方案,4275人分配至阿替洛尔±利尿剂方案),试验期内治疗中位数5.5年,通过医院与死亡记录关联随访长达21年(中位数17.4年)。其中一个亚组(n = 2156)在试验结束6年后接受问卷和门诊随访。试验期间的平均收缩压(SBP)和就诊间SBP标准差(变异性)来自超过100,000次血压测量。用Cox模型估计试验期间血压及变异性与试验后事件的风险比,以及分配的治疗与预设结局的风险比。
主要发现
以下为作者报告的结果。数字须连同人群和不确定性一起阅读。
- 1试验期间平均SBP可预测日后心血管事件(每10 mmHg的HR为1.14,95%置信区间1.10-1.17,P < .001),而独立于平均值的收缩压变异性是更强的预测因素(每5 mmHg的HR为1.22,95%置信区间1.18-1.26,P < .001),即使在血压控制良好的人中也是如此。
- 221年随访中,与基于阿替洛尔的治疗相比,基于氨氯地平的治疗降低了卒中(HR 0.82,95%置信区间0.72-0.93,P = .003)、总心血管事件(HR 0.93,0.88-0.98,P = .008)、总冠状动脉事件(HR 0.92,0.86-0.99,P = .024)和心房颤动(HR 0.91,0.83-0.99,P = .030)。
- 3心血管死亡的差异证据较弱(HR 0.91,95%置信区间0.82-1.01,P = .073)。
- 4非致死性心肌梗死与致死性冠心病、心力衰竭及全因死亡率无显著差异。
局限与不确定性
- 1变异性介导药物差异的结论来自统计模型,在这种设计中无法证明中介关系。
- 2变异性来自试验期间的门诊血压,而非家庭或动态血压监测,且参与者是英国高血压成人。
- 3阿替洛尔方案是较老的治疗方案,这一比较未必反映当今一线用药选择。
- 4检验的结局较多,P值在.03附近的结果可能是偶然。本解读仅基于摘要。
对日常健康的启示
除了良好的平均值,各次测量之间的稳定性似乎同样重要,这意味着应保持测量规范,而不是追逐单次数值。这些结果并不意味着应该更换任何药物,用药选择应由医生决定。
如何联系自己的数据
家用血压计可以让你看到数周内的变异性:在相同时间、使用同一血压计和相同姿势测量,并把记录交给医生。家庭读数与这里使用的门诊读数并不完全相同,手腕或手表的估算值可靠性也较差。
如何理解这类证据
索引未明确确定具体研究设计,应先读方法;核对人群、对照、结局和不确定性,再判断能否作因果解释。
作者的结构化摘要 English
以下英文摘要按记录的开放许可转载,属于作者原始材料,不是 MoveVitals 的解读。上方已提供研究解读,分别说明作者结果与本站解释;重要结论可直接核对原文。
Background and aims
Visit-to-visit systolic blood pressure variability (BPV) is an important predictor of cardiovascular (CV) outcomes. The long-term effect of a period of blood pressure (BP) control, but with differential BPV, is uncertain. Morbidity and mortality follow-up of UK participants in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure-Lowering Arm has been extended for up to 21 years to determine the CV impact of mean systolic blood pressure (SBP) control and BPV during the trial, and amongst those allocated to amlodipine- and atenolol-based treatment.
Methods
Eight thousand five hundred and eighty hypertensive participants (4305 assigned to amlodipine ± perindopril-based and 4275 to atenolol ± diuretic-based treatment during the in-trial period (median 5.5 years) were followed for up to 21 years (median 17.4 years), using linked hospital and mortality records. A subgroup of participants (n = 2156) was followed up 6 years after the trial closure with a self-administered questionnaire and a clinic visit. In-trial mean SBP and standard deviation of visit-to-visit SBP as a measure of BPV, were measured using >100 000 BP measurements. Cox proportional hazard models were used to estimate the risk [hazard ratios (HRs)], associated with (i) mean with SBP and BPV during the in-trial period, for the CV endpoints occurring after the end of the trial and (ii) randomly assigned treatment to events following randomization, for the first occurrence of pre-specified CV outcomes.
Results
Using BP data from the in-trial period, in the post-trial period, although mean SBP was a predictor of CV outcomes {HR per 10 mmHg, 1.14 [95% confidence interval (CI) 1.10-1.17], P < .001}, systolic BPV independent of mean SBP was a strong predictor of CV events [HR per 5 mmHg 1.22 (95% CI 1.18-1.26), P < .001] and predicted events even in participants with well-controlled BP. During 21-year follow-up, those on amlodipine-based compared with atenolol-based in-trial treatment had significantly reduced risk of stroke [HR 0.82 (95% CI 0.72-0.93), P = .003], total CV events [HR 0.93 (95% CI 0.88-0.98), P = .008], total coronary events [HR 0.92 (95% CI 0.86-0.99), P = .024], and atrial fibrillation [HR 0.91 (95% CI 0.83-0.99), P = .030], with weaker evidence of a difference in CV mortality [HR 0.91 (95% CI 0.82-1.01), P = .073]. There was no significant difference in the incidence of non-fatal myocardial infarction and fatal coronary heart disease, heart failure, and all-cause mortality.
Conclusions
Systolic BPV is a strong predictor of CV outcome, even in those with controlled SBP. The long-term benefits of amlodipine-based treatment compared with atenolol-based treatment in reducing CV events appear to be primarily mediated by an effect on systolic BPV during the trial period.
来源与署名
Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial.
Gupta A, Whiteley WN, Godec T, Rostamian S, Ariti C, Mackay J, Whitehouse A, Janani L, Poulter NR, Sever PS, ASCOT-10 Investigators .
European heart journal · 2024-04-01
DOI: 10.1093/eurheartj/ehad814 ↗PubMed · 38291599 ↗Europe PMC · 记录的开放许可: cc by ↗摘要版权归原作者,依据来源记录的开放许可转载。中文译文辅助阅读,英文摘要用于核对术语与具体数值;本站的方法学解释与作者结论分别呈现。
MoveVitals 编辑解读 · 健康教育内容 · 未记录个人临床审阅
来源核验日期 2026-11-01
实用健康指南
放在一起读
昼夜活动节律紊乱与更高的死亡风险相关(109,365人)
在7项观察性研究、共109,365名参与者中,昼夜活动对比较弱(相对振幅较低)与更高的心血管死亡风险(风险比[HR]1.50,95%置信区间1.13至1.98)和全因死亡风险(HR 1.46,95%置信区间1.27至1.68)相关。证据基础小,又是观察性的,不能说明改善节律就能降低风险,疾病本身也可能扰乱节律。
Journal of the American Heart Association
五类运动都降低了静息血压,等长训练降幅最大
汇总270项随机试验、共15,827名参与者的结果,有氧、抗阻、联合、间歇和等长训练与无干预对照组相比都降低了静息血压(各P<0.001),其中等长训练降幅最大:收缩压下降8.24 mm Hg,舒张压下降4.00 mm Hg。各方式之间的排序部分来自间接比较,各试验也不尽相同,所以排序不是个人的运动处方。
British Journal of Sports Medicine
盐替代品使中国农村高危人群的卒中、主要心血管事件和死亡率下降
在中国农村600个村庄、20,995名有卒中史或年龄在60岁及以上且有高血压的人中,使用盐替代品(氯化钠75%、氯化钾25%)的卒中发生率低于普通盐:平均随访4.74年,每1000人年29.14次对33.65次(率比0.86,95%置信区间0.77至0.96;P=0.006)。死亡也更低(率比0.88),严重高钾血症事件没有显著增多,但试验为开放标签设计,且在中国农村开展。
The New England Journal of Medicine
智能手表脉搏不规则提醒较少见,做贴片检查者34%确有房颤
在419,297名没有已知心房颤动(房颤)的苹果手表用户中,0.52%收到脉搏不规则提醒;返还可用心电贴片的450人中,34%确认有房颤(97.5%置信区间29至39)。提醒发出时恰有贴片记录的,通知的阳性预测值为0.84(95%置信区间0.76至0.92),但收到提醒者中仅20.8%返还了贴片,没有收到提醒的人未被监测,所以手表没有提醒并不能排除房颤。
The New England Journal of Medicine

